NPRA Malaysia trials new timelines for variation applications

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

NPRA Malaysia trials new timelines for variation applications

INICIO/Políticas y legislación | Posted 05/11/2024 0 Post your comment

In May 2024, Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) announced that it will trial new timelines for variation applications of registered pharmaceutical products and natural health supplements (TMHS).

The new guidelines aim to enhance efficiency in post-approval changes. From 1 June 2024, they will be tested in a one-year pilot study. The revised timelines vary from 10 to 150 working days depending on the type of product and variation.

Grouped applications are those that could take up to 150 working days. The original timelines are outlined in the Malaysian Variation Guideline for Pharmaceutical Products (MVG), Malaysian Variation Guideline for Biologics (MVGB), and Malaysian Variation Guideline for Natural and Health Supplement Products.

NPRA noted that they encourage product registration holders to plan accordingly. However, applications exceeding the permitted variations will not be rejected but may face extended review periods. Overall, they stated that the new timelines should, ‘provide greater clarity and more effective monitoring’.

In addition, it was noted that applicants must attach a cover letter that summarizes the changes for each variation application. NPRA expects applicants to include information related to the proposed variation category, a brief description and justification of the proposed variation. If available, approvals from the country of origin's national regulatory agency or reference agencies should be included.

Malaysia has a well-established biosimilars approval pathway, with guidance first published in 2008 that was based on the EMA’s approval system [1]. The country has now approved over 30 biosimilar products and if effective, these new variation timelines should strengthen their position.

PanGen gains Malaysian approval for epoetin alfa biosimilar

LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Los nueve fármacos biológicos más vendidos en 2023

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Los nueve fármacos biológicos más vendidos en 2023

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars regulation, clinical trials, approval and adverse events in Malaysia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Nov 5]. Available from: www.gabionline.net/biosimilars/research/Biosimilars-regulation-clinical-trials-approval-and-adverse-events-in-Malaysia

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.